Genocea Biosciences, Inc. announced the appointment of Narinder Singh as senior vice president of pharmaceutical sciences and manufacturing. Mr. Singh will be responsible for overseeing Genocea's manufacturing strategy including for GEN-009, the company's personal neoantigen cancer vaccine candidate. Mr. Singh has more than 20 years of experience in process development, scale-up, technical operations and manufacturing supply chain of biopharmaceuticals. Prior to joining Genocea, Mr. Singh was Vice President of Drug Product Development and Manufacturing at Momenta Pharmaceuticals where he built an integrated drug product group to support Momenta's expanding portfolio of biosimilars and novel biologics pipeline.